Antimicrobial Peptides, An Avenue to Treat Neurodegradation?

Shimon Shatzmiller^*, Inbal Lapidot & Galina Zats- Mordechai

Department of Chemical Sciences, Ariel University, Ariel Israel

Shimon Shatzmiller, Department of Chemical Sciences, Ariel University, Ariel Israel.

Keywords: Neurodegenerative; Diabetes 1,2 and 3; Peptide Surrogates; N-Methyl Peptide Mimics; Dihydropyridine; Azepine

Abstract

It is 20 years that the acceptance of the Amyloid hypothesis [1] by many researchers that worked very intensively on that basis to find remedy for neurodegenerative diseases. The current state of the art is: although this gave abundant opportunities, only 5 drugs, which do not cure the diseases, are approved by the FDA and those are for palliative therapies. There are new perspectives that combine many of the Amyloid diseases under one roof. The relations between Diabetes II and Alzheimer’s (type 3 diabetes [2]). That approach might open new avenues for drug developments. The paper discuses some older and modern approaches to base drug development research.

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).